Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Apr;61(8):1391-1395.
doi: 10.1111/apt.70024. Epub 2025 Feb 18.

Comparison Between Dynamic Models for Predicting Response to Corticosteroids in Alcohol-Associated Hepatitis: A Global Cohort Study

Affiliations
Comparative Study

Comparison Between Dynamic Models for Predicting Response to Corticosteroids in Alcohol-Associated Hepatitis: A Global Cohort Study

Francisco Idalsoaga et al. Aliment Pharmacol Ther. 2025 Apr.

Abstract

Several dynamic models predict mortality and corticosteroid response in alcohol-associated hepatitis (AH), yet no consensus exists on the most effective model. This study aimed to assess predictive models for corticosteroid response and short-term mortality in severe AH within a global cohort. We conducted a multi-national study of patients with severe AH treated with corticosteroids for at least 7 days, enrolled between 2009 and 2019. Dynamic models-Lille-4, Lille-7, trajectory of serum bilirubin (TSB), and neutrophil-to-lymphocyte ratio (NLR)-were used to estimate 30- and 90-day mortality. Lille-7 demonstrated the highest accuracy for both 30- and 90-day mortality.

Keywords: alcohol; alcoholic cirrhosis; alcohol‐associated liver disease; alcohol‐related hepatitis; cirrhosis; end‐stage liver disease; outcome prediction.

PubMed Disclaimer

Conflict of interest statement

R.B.: consulting for GSK, Novo Nordisk and Boehringer‐Ingelheim. J.G.A.: consulting for 89bio, Agomab, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Terumo, Boston Pharmaceuticals. Grant support: Salix, Gilead, Cook. L.S.: Consulting for Abbvie, Gilead, Astellas, Worwag, ProMed. D.J.H.: Lecturing for Abbvie, Gilead, Astellas, ProMed.

Figures

FIGURE 1
FIGURE 1
ROC curves of risk scores to predict mortality by 30 days and 90 days. The figure displays the performance of different risk scores in predicting mortality, with panel (A) representing the 30‐day mortality predictions and panel (B) illustrating the 90‐day mortality predictions. Lille‐4, Lille at day 4; Lille‐7, Lille at day 7; NLR, delta neutrophil‐to‐lymphocyte ratio; TSB, trajectory serum bilirubin.

References

    1. Gao B. and Bataller R., “Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets,” Gastroenterology 141, no. 5 (2011): 1572–1585. - PMC - PubMed
    1. Bataller R., Arab J. P., and Shah V. H., “Alcohol‐Associated Hepatitis,” New England Journal of Medicine 387, no. 26 (2022): 2436–2448, 10.1056/NEJMra2207599. - DOI - PubMed
    1. Arab J. P., Roblero J. P., Altamirano J., et al., “Alcohol‐Related Liver Disease: Clinical Practice Guidelines by the Latin American Association for the Study of the Liver (ALEH),” Annals of Hepatology 18, no. 3 (2019): 518–535. - PubMed
    1. Arab J. P., Díaz L. A., Baeza N., et al., “Identification of Optimal Therapeutic Window for Steroid Use in Severe Alcohol‐Associated Hepatitis: A Worldwide Study,” Journal of Hepatology 75, no. 5 (2021): 1026–1033. - PMC - PubMed
    1. Ayares G., Idalsoaga F., Díaz L. A., Arnold J., and Arab J. P., “Current Medical Treatment for Alcohol‐Associated Liver Disease,” Journal of Clinical and Experimental Hepatology 12, no. 5 (2022): 1333–1348. - PMC - PubMed

LinkOut - more resources